Samaritan Pharmaceuticals Inc. (OTC BB:SPHC.OB), announced today, it will present its late-stage preclinical drug candidates at the BIO International Convention 2007 in Boston, MA, on May 8, 2007 at 3 PM EDT, Room D, in the Business Forum. Samaritan will highlight its novel Alzheimer's drug, Caprospinol (SP-233) as the closest to potentially enter Phase I human clinical trials, as well as present its acute coronary drug candidate (SP-1000) and its oral hepatitis C drug candidate (SP-10T1).

The FDA granted Caprospinol (SP-233) investigational new drug (IND) status October 30, 2006.

Caprospinol (SP233) is a small molecule therapeutic, indicated for Alzheimer's disease.
1. Caprospinol actually removed beta-amyloid plague in-vivo
2. Caprospinol has been shown to restore memory in rats (Morrison Water-maze)
3. Caprospinol offers a subjective endpoint to evaluate its efficacy

The ability of Caprospinol to stop and even eliminate amyloid plaque formation, in both the cortex, and in the CA1 of the hippocampus structures, as well as the drug's demonstrated ability to restore memory in rats, suggests that Caprospinol may be the first major breakthrough in the actual treatment of Alzheimer's. This hypothesis is further posited based on the drug's favorable safety profile.

Globally, an estimated 4.5 million people suffer from Alzheimer's disease. This number is expected to increase to 7.7 million in 2030. Unlike many diseases, Alzheimer's is a slow debilitating disease that dramatically affects the infected and their loved ones for years. Currently, no cure has been found for Alzheimer's disease, nor is there a proven method to slow its progression. Additionally, approved treatments that exist today are cost-prohibitive and minimally effective.

About Samaritan Pharmaceuticals: ``We LIV... to Save Lives.''
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease; cancer; cardiovascular disease, HIV, and Hepatitis C. Samaritan partnered its “oral” entry inhibitor HIV drug SP-01A, with Pharmaplaz, Ireland; and is evaluating the use of Caprospinol, SP-233 for Alzheimer's disease patients; the use of SP-1000 for acute coronary disease patients; and the use of SP-10T1 as an "oral treatment" for Hepatitis-C patients. In addition, Samaritan has acquired the marketing and sales rights to sell nine revenue-generating products in Greece and/or various Eastern European countries. Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.

Disclaimer:
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.